The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy.
Name: SCT-I10A
Name: SCT510
Name: Sorafenib 200mg
Description: PFS evaluated by investigator based on RECIST V1.1
Measure: PFS Time: up to 3yearsDescription: PFS evaluated by BICR based on mRECIST.
Measure: PFS Time: up to 3yearsDescription: ORR evaluated by BICR based on RECIST V1.1.
Measure: Objective response rate (ORR) Time: up to 3yearsDescription: ORR evaluated by BICR based on mRECIST.
Measure: ORR Time: up to 3yearsDescription: ORR evaluated by investigator based on RECIST V1.1
Measure: ORR Time: up to 3yearsAllocation: Randomized
Parallel Assignment
There is one SNP
SCT-I10A in Combination With SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (HCC): A Multicenter, Randomized, Open-label,Phase 2/3 Trial. --- I10A ---
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy. --- I10A ---
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy. --- I10A --- --- I10A ---
Serum concentration of SCT-I10A and SCT510. --- I10A ---